Arax Advisory Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Arax Advisory Partners’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$827K	Buy	19,660 +5,389	+38%	+$172K	0.01%	1322
2026 Q1	$377K	Buy	14,271 +389	+3%	+$11.4K	0.01%	753
2025 Q4	$402K	Buy	+13,882	New	+$417K	0.01%	689
2025 Q3	–	Sell	-17,746	Closed	-$432K	–	3631
2025 Q2	$432K	Buy	17,746 +1,792	+11%	+$39.3K	0.02%	430
2025 Q1	$331K	Buy	15,954 +15,538	+3,735%	+$390K	0.02%	402
2024 Q4	$9.78K	Hold	416	–	–	﹤0.01%	1497
2024 Q3	$10.6K	Buy	+416	New	+$10.6K	﹤0.01%	1384
2020 Q4	$1K	Buy	+8	New	+$637	﹤0.01%	686

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Arax Advisory Partners's ARKG Position: Q2 2026 in Review

Arax Advisory Partners increased its ARK Genomic Revolution ETF (ARKG) stake by 38% in Q2 2026, buying an estimated $172K and bringing the position to 19,660 shares worth $827K. The position accounts for 0.01% of the portfolio, ranked #1322.

Arax Advisory Partners first reported a position in ARKG in Q4 2020 and has held it in 8 quarters since. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Arax Advisory Partners held 19,660 shares of ARK Genomic Revolution ETF worth $827K as of Q2 2026.
Arax Advisory Partners bought 5,389 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $172K.
ARK Genomic Revolution ETF made up 0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1322 holding.
Arax Advisory Partners first reported a position in ARK Genomic Revolution ETF in Q4 2020 and has held it in 8 quarters since.
271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.